Hyrimoz FDA Approval History
FDA Approved: Yes (First approved October 30, 2018)
Brand name: Hyrimoz
Generic name: adalimumab-adaz
Dosage form: Injection
Company: Sandoz Inc.
Treatment for: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Maintenance, Ulcerative Colitis, Plaque Psoriasis
Hyrimoz (adalimumab-adaz) is an anti-TNF-α monoclonal antibody biosimilar to Humira, approved for the treatment of various inflammatory diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.
Development Timeline for Hyrimoz
| Date | Article |
|---|---|
| Oct 31, 2018 | Approval FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.